A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes

American Heart Journal

Volumn 153, Issue 3, 2007, Pages 445.e1-445.e6

  Stocker, Derek J ^a   Taylor, Allen J ^a   Langley, Roy W ^a   Jezior, Matthew R ^a   Vigersky, Robert A ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; METFORMIN; ROSIGLITAZONE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 33847403059     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2006.11.005     Document Type: Article

References (26)

1. Haffner S.M., Greenberg A.S., Weston W.M., et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106 (2002) 679-684
2. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
3. Van De Ree M.A., Huisman M.V., Princen H.M., et al. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 166 (2003) 129-135
4. Taylor A.J., Kent S.M., Flaherty P.J., et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 106 (2002) 2055-2060
5. Chu N.V., Kong A.P., Kim D.D., et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 25 (2002) 542-549
6. Mohanty P., Aljada A., Ghanim H., et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 89 (2004) 2728-2735
7. Schulze M.B., Rimm E.B., Li T., et al. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care 27 (2004) 889-894
8. Ridker P.M., Cannon C.P., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
9. Kent S.M., Coyle L.C., Flaherty P.J., et al. Marked low-density lipoprotein cholesterol reduction below current national cholesterol education program targets provides the greatest reduction in carotid atherosclerosis. Clin Cardiol 27 (2004) 17-21
10. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352 (2005) 29-38
11. Hodis H.N., Mack W.J., LaBree L., et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 128 (1998) 262-269
12. Waters D., Higginson L., Gladstone P., et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 89 (1994) 959-968
13. Carter A.M., Bennett C.E., Bostock J.A., et al. Metformin reduces C-reactive protein but not complement factor C3 in overweight patients with type 2 diabetes mellitus. Diabet Med 22 (2005) 1282-1284
14. Yatagai T., Nakamura T., Nagasaka S., et al. Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects. Diabetes Res Clin Pract 63 (2004) 19-26
15. Dandona P., Aljada A., Ghanim H., et al. Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J Clin Endocrinol Metab 89 (2004) 5043-5047
16. Satoh N., Ogawa Y., Usui T., et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26 (2003) 2493-2499
17. Aljada A., Garg R., Ghanim H., et al. Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action?. J Clin Endocrinol Metab 86 (2001) 3250-3256
18. Langenfeld M.R., Forst T., Hohberg C., et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 111 (2005) 2525-2531
19. Pfutzner A., Marx N., Lubben G., et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 45 (2005) 1925-1931
20. Calkin A.C., Forbes J.M., Smith C.M., et al. Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler Thromb Vasc Biol 25 (2005) 1903-1909
21. Levi Z., Shaish A., Yacov N., et al. Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model. Diabetes Obes Metab 5 (2003) 45-50
22. Phillips J.W., Barringhaus K.G., Sanders J.M., et al. Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes. Circulation 108 (2003) 1994-1999
23. Koshiyama H., Shimono D., Kuwamura N., et al. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 86 (2001) 3452-3456
24. Minamikawa J., Tanaka S., Yamauchi M., et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 83 (1998) 1818-1820
25. Takagi T., Akasaka T., Yamamuro A., et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol 36 (2000) 1529-1535
26. Jialal I., Devaraj S., and Venugopal S.K. C-reactive protein: risk marker or mediator in atherothrombosis?. Hypertension 44 (2004) 6-11